BPC-157
Day 1 · Free base + acetate
Favorable recommendation
Both form-level questions received the same favorable tally.
- 8
- Yes
- 6
- No
- 1
- Abstain
Day 2 live · Updated after Epitalon
PCAC peptide vote tracker
One clear view of the FDA webcast, the Section 503A voting questions, and every verified result as it lands.
Updated July 24 after the Epitalon vote
Vote tallies verified from the FDA webcast
Results board
Seven peptides. Fourteen questions.
Favorable Unfavorable Pending
KPV
Day 1 · Free base + acetate
Favorable recommendation
The paired form questions received favorable recommendations.
- 8
- Yes
- 6
- No
- 1
- Abstain
TB-500
Day 1 · Free base + acetate
Favorable recommendation
The committee delivered another favorable 8–6–1 result.
- 8
- Yes
- 6
- No
- 1
- Abstain
MOTS-c
Day 1 · Free base + acetate
Favorable recommendation
The committee delivered a favorable 7–5–2 result.
- 7
- Yes
- 5
- No
- 2
- Abstain
Emideltide (DSIP)
Day 2 · Free base + acetate
Unfavorable recommendation
The committee voted 6–7–1, an unfavorable recommendation.
- 6
- Yes
- 7
- No
- 1
- Abstain
Epitalon
Day 2 · Free base + acetate
Favorable recommendation
The committee delivered a favorable 7–4–1 result.
- 7
- Yes
- 4
- No
- 1
- Abstain
Semax
Day 2 · Free base + acetate
Awaiting result
Scheduled for Friday afternoon.
—
What moved the room
Two records from the hearing
The testimony behind two of Thursday’s favorable recommendations.
16M+
BPC-157 · real-world record
More than 16 million doses, with seven complaints.
Dr. Alex Tatem presented aggregated BPC-157 use with no clear attributable adverse safety signal.
Watch the testimony- Complaints
- 7
- Clear signal
- None
190K
TB-500 · testimony
A case built on human context, real-world use, and FDA’s own searches.
Tatem connected full-length thymosin beta-4 trials, nearly 190,000 compounded vials, no serious complaints, and no human adverse-event cases found in FDA’s searches.
Watch Tatem’s caseRestoring Category 1 would move demand away from grey-market research products and under regulated compounding oversight.
What happens next
A favorable PCAC vote is a recommendation—not the final list update.
BPC-157, KPV, TB-500, MOTS-c, and Epitalon now carry favorable committee recommendations. Emideltide does not. FDA still must complete the federal process before the Section 503A Bulks List changes.
Where can I watch the PCAC live stream?
FDA is streaming the July 2026 PCAC meeting on YouTube. The July 23 and July 24 official webcasts are linked directly from this tracker.
Which peptides is PCAC voting on?
The July 2026 PCAC peptide agenda covers BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Epitalon, and Semax in free-base and acetate forms.
What are the latest PCAC peptide vote results?
BPC-157, KPV, TB-500, MOTS-c, and Epitalon received favorable committee recommendations. Emideltide (DSIP) received an unfavorable recommendation. Semax remains pending.
What time does the July 24 PCAC meeting start?
The July 24 PCAC meeting starts at 8 a.m. Eastern and covers emideltide (DSIP), Epitalon, and Semax.
Can I watch a PCAC webcast replay?
Yes. The same official FDA YouTube links remain available for replay after each PCAC livestream ends.
What does PCAC stand for?
PCAC stands for Pharmacy Compounding Advisory Committee, the FDA advisory committee discussing the Section 503A Bulks List peptide nominations.
One vote remains